AUS
NZ
UK
CA
USA
IND
Highlights
- Yandal Resources advances key drilling efforts at Caladan
- Orthocell reports first U.S. revenue from Remplir™
- Race Oncology secures HREC approvals for Phase 1 trial
The S&P/ASX Small Ordinaries index continues to reflect broader investor sentiment as it trends slightly lower this week. Despite this modest pullback, several emerging small-cap companies are making significant operational strides that are capturing attention across exploration, biotech, and advanced materials sectors. While quarterly updates will soon dominate headlines, recent activity showcases promising developments beyond the ASX 200 share price movers, highlighting innovation and execution in the small-cap space.
Yandal Resources (ASX:YRL) has taken a step forward in its exploration ambitions with its large-scale air-core drilling program at the Caladan target. The company recently received assay results from 16 holes, part of an extensive campaign launched in June. These results represent just a portion of the 100 holes already drilled across over 10,000 metres, with further drilling underway. The full program will cover a substantial strike length, indicating strong commitment to uncovering potential mineralisation across the 6.4-kilometre zone.
In the medical technology sphere, Orthocell (ASX:OCC) achieved a notable commercial breakthrough with the first sales of its Remplir™ nerve repair device in the United States. This milestone follows initial surgical procedures that began in late June 2025. The move not only validates the clinical utility of the product but also places the company firmly on the path to expanding within the sizeable US peripheral nerve repair market. Establishing early revenue in this high-potential territory marks a foundational moment in Orthocell’s international strategy.
Meanwhile, Race Oncology (ASX:RAC) has secured ethical clearance to begin its Phase 1 clinical trial (RAC-010) of its lead asset RC220, in combination with doxorubicin. The Human Research Ethics Committee (HREC) approvals from the University of Hong Kong will enable studies at Queen Mary and Prince of Wales Hospitals. With final regulatory permissions progressing and site activations expected soon, Race Oncology is laying the groundwork for vital clinical validation that could influence future therapeutic developments.
In the materials innovation sector, Green360 Technologies (ASX:GRT) has started bulk calcining operations for high-purity kaolin sourced from its Pittong facility. This processed kaolin will be converted into metakaolin, a highly reactive material with applications in sustainable construction and value-added industrial products. This move represents a shift towards downstream processing and vertical integration, positioning the company to benefit from higher-margin outputs.
From resource-rich exploration to biotech trials and advanced material production, these operational updates highlight how ASX-listed small caps are pushing forward with tangible progress. While they may not yet feature on ASX 200 indices, the traction gained by companies like Yandal, Orthocell, Race Oncology, and Green360 underscores the diversity and innovation within Australia’s smaller-cap ecosystem.
